Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
Charities must work to help pharma and academia prioritise and accelerate paediatric treatments.
BI developing combinations with its own checkpoint inhibitors